Navigation Links
Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
Date:9/29/2009

FARMINGDALE, N.Y., Sept. 29 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced plans to release fourth quarter and fiscal year ended June 30, 2009 financial results on Thursday afternoon, October 1, 2009. Michael A. McManus, President and Chief Executive Officer and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Thursday,October 1, 2009 to discuss the Company's fourth quarter and fiscal 2009 financial results.

Shareholders and other interested parties may participate in the conference call by dialing (866) 515-2909 (domestic) or (617) 399-5123 (international) and entering access code 61977194, a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available approximately 2 hours after the event through October 8, 2009. The dial-in number to listen to the recording is (888) 286 8010 or (617) 801 6888. The replay access code is 35358896.

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

    Investor Relations Contact:
    Kevin M. McGrath
    Cameron Associates, Inc.
    212 245 4577
    Kevin@cameronassoc.com

SOURCE Misonix, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
2. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
3. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
4. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
7. PLC Systems Reports Fourth Quarter 2007 Results
8. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
9. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
10. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
11. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and VANCOUVER, British Columbia , Feb. ... OGXI ) today announced its year end 2016 financial ... In January 2017, OncoGenex, and Achieve Life Science, Inc., a ... entered into a definitive merger agreement under which OncoGenex ... of the proposed merger, Achieve,s stockholders are expected to ...
(Date:2/23/2017)... 22, 2017 This report analyzes analyzes the worldwide markets ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2015 through 2022. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/23/2017)... YORK , Feb. 22, 2017 Medical ... medical intervention. Medical imaging is performed to reveal the ... examine and diagnose the medical condition. It plays a ... the treatment process as it is taken into consideration ... medical imaging include X-rays, SPECT/PET, ultrasound, CT, and MRI. ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... (PRWEB) February 23, ... the nation to come together to combine its favorite springtime ... its favorite fruit – apples! To celebrate National Nutrition Month, ... the “Apple Madness” bracket tournament – a five-week, five-round online ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that ... of CM-AT in children aged 3-8 with Autism, is now enrolling at three new ... children across the United States. , “There are currently no approved drugs that ...
(Date:2/23/2017)... Va. (PRWEB) , ... February 23, 2017 , ... ... or problems. He has also continued to spiritually evolve, which is the purpose of ... book “ Our Spiritual Truths ” (published by Balboa Press) attempts to guide readers ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company ... announced its products are coming soon to Amazon.com, the world’s largest online retailer. ... a means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d ...
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, the leading ... of hospitals, health information exchanges, physicians and patients, announced today that SES Direct ... Edition Health IT Module Certification via Drummond Group LLC, an Authorized Certification Body ...
Breaking Medicine News(10 mins):